E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
Andrés E. Quesada,Rajyalakshmi Luthra,Elias Jabbour,Keyur P. Patel,Joseph D. Khoury,Zhenya Tang,Héctor M. Alvarez,Saradhi Mallampati,Guillermo Garcia-Manero,Guillermo Montalban-Bravo,L. Jeffrey Medeiros,Rashmi Kanagal-Shamanna +11 more
TL;DR: In this article, a 52-yr-old woman presented with therapy-related acute myeloid leukemia and a bone marrow biopsy showed 21% blasts with a myelous phenotype and no other notable features such as abnormal eosinophils.
Journal ArticleDOI
Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings
Ruben A. Mesa,Yun Su,Adrien Woolfson,Josef T. Prchal,Kathleen Turnbull,Elias Jabbour,Robyn M. Scherber,Alan L. Shields,Meaghan Krohe,Funke Ojo,Farrah Pompilus,Joseph C. Cappelleri,Claire N. Harrison +12 more
TL;DR: The findings demonstrate the comprehensiveness of the MPN-SD in assessing MF symptoms in both ruxolitinib-experienced and ruxolic-naïve patients, while remaining easy for patients to understand and complete.
Journal ArticleDOI
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Maria R Vazquez,Hagop M. Kantarjian,Gautam Borthakur,Susan O'Brien,Srdan Verstovsek,Farhad Ravandi,Alessandra Ferrajoli,Jorge E. Cortes,Tapan M. Kadia,William G. Wierda,Guillermo Garcia-Manero,Sara Dellasala,Kathleen A Kehr,Sherry Pierce,Mary Beth Rios,Elias Jabbour +15 more
TL;DR: This analysis was done to investigate a 20-year outcome of Imatinib in patients treated with Chronic Phase (CP) Chronic Myeloid Leukemia after interferon-alpha failure and intention to treat (ITT) responses are available for 63 patients.
Journal ArticleDOI
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia
Kehinde Adekola,Antonio Di Stasi,Roberto Ferro,Sairah Ahmed,Marcos de Lima,Betul Oran,Borje S. Andersson,Alfonso Quintás-Cardama,Elias Jabbour,Hagop M. Kantarjian,Jorge E. Cortes,Richard E. Champlin,Stefan O. Ciurea +12 more
TL;DR: Post-transplant cyclophosphamide (PTCy), in addition to tacrolimus and mycophenolate, has been effective in preventing GVHD and was associated with lower treatmentrelated mortality in this type of transplant, indicating ECP may be effective as prophylactic therapy for cGvHD.
Journal ArticleDOI
Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Guillermo Montalban-Bravo,Prithviraj Bose,Yesid Alvarado,Naval Daver,Farhad Ravandi,Gautam Borthakur,Koichi Takahashi,Michael Andreeff,Jorge E. Cortes,Courtney D. DiNardo,Elias Jabbour,Tapan M. Kadia,Steven M. Kornblau,Maro Ohanian,Xuelin Huang,Graciela M. Nogueras-Gonzalez,Kristy Bodden,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +19 more
TL;DR: Guadecitabine is a next generation hypomethylating agent with increase in activity in patients with higher risk MDS and CMML and its potential to improve response and survival outcomes is fundamental.